SGH
VRTX icon

Sivik Global Healthcare’s Vertex Pharmaceuticals VRTX Stock Holding History

Sivik Global Healthcare’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-20,000
Closed -$2K – 79
2014
Q2 		$2K Buy
+20,000
New +$1.4M ﹤0.01% 70

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Sivik Global Healthcare's VRTX Position: Q2 2026 in Review

Sivik Global Healthcare held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 10,000 shares worth $4.46M. The position accounts for 3.39% of the portfolio, ranked #9.

Sivik Global Healthcare first reported a position in VRTX in Q2 2014 and has held it in 38 quarters since. The position peaked at $7.6M in Q3 2017. 1,014 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sivik Global Healthcare held 10,000 shares of Vertex Pharmaceuticals worth $4.46M as of Q2 2026.
  • Sivik Global Healthcare left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 3.39% of Sivik Global Healthcare's portfolio in Q2 2026, its #9 holding.
  • Sivik Global Healthcare first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 38 quarters since.
  • Sivik Global Healthcare's Vertex Pharmaceuticals position peaked at $7.6M in Q3 2017.
  • 1,014 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sivik Global Healthcare's 13F filing for Q2 2026, filed 20 Jul 2026.